STARTING SPINRAZA / HOW TO START

Help your patients begin treatment and access support

for SPINRAZA

SPINRAZA Start Form:

There are 2 ways to complete the Start Form for SPINRAZA:

Download in English or Spanish here:

SPINRAZA Start Form in EnglishDownload the Start Form (English)
SPINRAZA Start Form in SpanishDownload the Start Form (Spanish)

OR

Complete the E-sign Start Form

Access the E-sign Start Form

Using either form, complete the healthcare provider section to prescribe SPINRAZA and enroll your patient in support services.

Send the completed Start Form and copies of the insurance/pharmacy benefit cards to Biogen by fax or email.

Fax Icon

Fax: 1-888-538-9781

Email Icon

Email as an attachment: StartForm@biogen.com
Please note this email address is an unattended inbox and is for Start Forms only.

Once Biogen receives the SPINRAZA Start Form, a SPINRAZA Family Access Manager (FAM) or Lead Case Manager (LCM) will contact the patient or parent/guardian to help them navigate the process.

Remember to conduct the following laboratory tests at baseline and prior to each dose of SPINRAZA and as clinically needed:

  • Platelet count
  • Prothrombin time; activated partial thromboplastin time
  • Quantitative spot urine protein testing
SPINRAZA Patient Brochure:

Discuss the benefits and risks of SPINRAZA with appropriate patients. Download the brochure below to help start the conversation.

SPINRAZA patient brochure Information for Patients

Biogen takes the confidentiality of personal information seriously.

The benefits for patients of granting consent include:

  • Expediting enrollment into SMA360°™* patient support services from Biogen, which includes help in areas such as treatment logistics, insurance, and financial assistance
  • Giving Biogen access to the status of the prescription should assistance be required

*SMA360° services from Biogen are available only to those who have been prescribed SPINRAZA. SMA360° is intended for US residents only.

Questions about support or treatment logistics?

Contact your Biogen Rare Disease Account Executive

SPINRAZA should be administered by, or under the direction of, a specially trained healthcare professional able to perform lumbar punctures1

EXPLORE DOSING & ADMINISTRATION
GO TO ACCESS & REIMBURSEMENT

INDICATION

SPINRAZA® (nusinersen) is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

IMPORTANT SAFETY INFORMATION

Coagulation abnormalities and thrombocytopenia, including acute severe thrombocytopenia, have been observed after administration of some antisense oligonucleotides. Patients may be at increased risk of bleeding complications.

In the sham-controlled studies for patients with infantile-onset and later-onset SMA, 24 of 146 SPINRAZA-treated patients (16%) with high, normal, or unknown platelet count at baseline developed a platelet level below the lower limit of normal, compared to 10 of 72 sham-controlled patients (14%). Two SPINRAZA-treated patients developed platelet counts <50,000 cells per microliter, with the lowest level of 10,000 cells per microliter recorded on study day 28.

Renal toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. SPINRAZA is present in and excreted by the kidney. In the sham-controlled studies for patients with infantile-onset and later-onset SMA, 71 of 123 SPINRAZA-treated patients (58%) had elevated urine protein, compared to 22 of 65 sham-controlled patients (34%).

Laboratory testing and monitoring to assess safety should be conducted. Perform a platelet count, coagulation laboratory testing, and quantitative spot urine protein testing at baseline and prior to each dose of SPINRAZA and as clinically needed.

Severe hyponatremia was reported in an infant treated with SPINRAZA requiring salt supplementation for 14 months.

Cases of rash were reported in patients treated with SPINRAZA.

SPINRAZA may cause a reduction in growth as measured by height when administered to infants, as suggested by observations from the controlled study. It is unknown whether any effect of SPINRAZA on growth would be reversible with cessation of treatment.

The most common adverse reactions (≥20% of SPINRAZA-treated patients and ≥5% more frequently than in control patients) that occurred in the infantile-onset controlled study were lower respiratory infection and constipation. Serious adverse reactions of atelectasis were more frequent in SPINRAZA-treated patients (18%) than in control patients (10%). Because patients in this controlled study were infants, adverse reactions that are verbally reported could not be assessed. The most common adverse reactions that occurred in the later-onset controlled study were pyrexia, headache, vomiting, and back pain. Post-lumbar puncture syndrome has also been observed after the administration of SPINRAZA.

Please see full Prescribing Information.

As a courtesy, our full Prescribing Information is also available en Español. For prescribing decisions, please refer to official approved labeling.

Reference

1. SPINRAZA. Prescribing Information. Biogen; 2024.

Stay Connected
Sign up with us to receive news and support information and hear about upcoming events.

ABOUT SMA
What Is SMA? Multidisciplinary Care
Why SPINRAZA?
About SPINRAZA How SPINRAZA Works Presymptomatic Efficacy Early-Onset Efficacy Later-Onset Efficacy Real-World Evidence Safety
Starting SPINRAZA
How to Start Dosing & Administration
Patients on Therapy
Patients on Therapy
RESOURCE LIBRARY
Access & Reimbursement SMA360°™ Patient Support Events Video Hub

©2025 Biogen. All rights reserved.
This site is intended for US Healthcare Professionals only.
SPZ-US-3383 v11 02/25